Shares of Precigen (NASDAQ:PGEN) added ~34% in the premarket on Friday after the U.S. Food and Drug Administration (FDA) ...

Earlier today, it was announced that Precigen’s PAPZIMEOS (formerly PRGN-2012) was FDA-approved for adults with RRP. Read why ...

Shares in biopharmaceutical company Precigen (PGEN) rocketed higher today after the U.S. Food and Drug Administration gave ...

Precigen's immunotherapy for a rare respiratory disease has become the first treatment to win U.S. regulatory approval for ...

Precigen's Papzimeos wins FDA approval as the first therapy for adult recurrent respiratory papillomatosis, showing durable results in clinical trials.

In the last three months, Precigen Inc. (NASDAQ: PGEN) stock lost 23%. Here is what the fund said: "Precigen Inc. (PGEN) declined 30% following a strong gain in the fourth quarter of 2020.

We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Precigen, Inc. (NASDAQ:PGEN) stands against other hot biotech stocks under $5 ...

"With the landmark FDA approval of PAPZIMEOS and broad label, all adult RRP patients are now eligible for access to the first and only approved therapy that targets the root cause of the disease," ...

At Precigen, a filing with the SEC revealed that on Thursday, Randal J. Kirk bought 96,686 shares of PGEN, for a cost of $1.41 each, for a total investment of $136,327.

Precigen, Inc. (NASDAQ:PGEN) ended Q3 2024 with a robust financial standing bolstered by a $30.9 million public offering in August. Research and development expenses rose $5.7 million (16%) in the ...